When Chevrolet revealed the 2027 Bolt last fall, the automaker referred to the electric hatchback as a "limited-run vehicle." At the time, we weren't quite sure what that meant. Typically, ...

I’ve been a devoted trackpad user since I first got my very own computer over 15 years ago. Since then I’ve tried dozens of mice, but none have truly been able to dethrone Apple’s Magic Trackpad ...

The reborn electric vehicle is derived from the previous Bolt EUV. 255 miles of range Base price of $28,995 (all prices include $1,395 destination charge) makes it the cheapest new EV One of the first ...

Custom buttons, gestures or scrolling tweaks suddenly not working on your Logitech mouse or keyboard on Mac? You’re not alone. The Logi Options+ app stopped working properly Tuesday, and the failure ...

The new Logitech Alto Keys 98 is a full size wireless mechanical keyboard with backlighting, long battery life and customisable keys. Logitech has announced a new mechanical keyboard. The Alto Keys ...

Middle-of-the-pack sound quality and flimsy materials give a bad first impression, but a comfortable and light fit makes the Lightspeed a solid everyday headset on a budget. PC Gamer's got your back ...

It’s the ultimate battle of the small Mac keyboards: Logitech MX Keys Mini vs. Apple Magic Keyboard. Choosing between these two premium compact keyboards is tough, and the decisions you make can ...

The 2027 Chevrolet Bolt returns as America’s cheapest EV, offering 255 miles of range, 150 kW fast charging, and advanced tech for under $30K. While the 2027 Bolt’s exterior design is similar to the ...

GM is bringing back its Chevrolet Bolt with a new model that it expects to account for much of its electric-vehicle volume next year. The company said Thursday its 2027 Chevrolet Bolt will begin ...

The starting price for the Bolt's LT comfort package is $29,990. It’s unclear how impactful losing the EV tax credits will be for Bolt sales. The Chevrolet Bolt is back ― for now. General Motors said ...

Bolt Biotherapeutics has halved its workforce for the second time in two years as the oncology biotech delays a readout of its lead immunotherapy. The company had previously been expecting initial ...